FDA rejects serelaxin for acute heart failure

The Food and Drug Administration has decided that more evidence of serelaxin’s efficacy as a treatment for acute heart failure is needed before the drug can be approved in the United States, Novartis...

Field of Interest: Cardiology
Type: News Item

RAS blocker prescriptions still lag for ACS patients

Fifteen percent of eligible patients treated for acute coronary syndrome still are not given ACE inhibitors or angiotensin receptor blockers as recommended, according to data from a quality...

Field of Interest: Cardiology
Type: News Item

No ACS approvals for rivaroxaban, Janssen announces

As expected, the Food and Drug Administration has declined to approve the oral anticoagulant rivaroxaban for treating acute coronary syndromes. The manufacturer of the factor Xa inhibitor, Janssen...

Field of Interest: Cardiology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness